Gallbladder CancerSymptoms, Doctors, Treatments, Advances & More
Learn About Gallbladder Cancer
- Gallbladder cancer
Common conditions include: Gallbladder Adenocarcinoma
Shishir Maithel is a Surgical Oncologist practicing medicine in Chicago, Illinois. He has been practicing medicine for over 26 years. Dr. Maithel is rated as an Elite provider by MediFind in the treatment of Gallbladder Cancer. He is also highly rated in 29 other conditions, according to our data. His clinical expertise encompasses Cholangiocarcinoma (Bile Duct Cancer), Gallbladder Cancer, Gallbladder Disease, Pancreaticoduodenectomy, and Hepatectomy. Dr. Maithel is board certified in American Board Of Surgery - Surgery (Certified).
Vanderbilt-Ingram Cancer Center
Kamran Idrees is a Colorectal Surgeon practicing medicine in Nashville, Tennessee. Dr. Idrees is rated as an Elite provider by MediFind in the treatment of Gallbladder Cancer. He is also highly rated in 25 other conditions, according to our data. His clinical expertise encompasses Gallbladder Cancer, Neuroendocrine Tumor, Pancreatic Islet Cell Tumor, Pancreaticoduodenectomy, and Pancreatectomy.
Emory Winship Cancer Institute
Juan Sarmiento is a General Surgeon practicing medicine in Atlanta, Georgia. He has been practicing medicine for over 39 years. Dr. Sarmiento is rated as an Elite provider by MediFind in the treatment of Gallbladder Cancer. He is also highly rated in 33 other conditions, according to our data. His clinical expertise encompasses Pancreatic Cancer, Gallbladder Cancer, Bile Duct Cysts, Pancreaticoduodenectomy, and Pancreatectomy. Dr. Sarmiento is board certified in American Board Of Surgery, 2001.
Summary: Checkpoint inhibitor therapy represents a significant advance in cancer care. The interaction between PD-1 and PD-L1 induces immune tolerance, and the inhibition of this interaction is an effective treatment strategy for numerous malignancies. Despite its demonstrated potential, immunotherapy is not currently thought to be an effective intervention in the treatment of several immunologically cold ...
Summary: This study will evaluate the effectiveness of T-DXd in patients with HER2-positive (IHC 3+) locally advanced, unresectable, or metastatic solid tumors who have received prior systemic treatment for metastatic or advanced disease and have no satisfactory alternative treatment options in a real-world setting in the US
Published Date: May 02, 2022
Published By: Genetic and Rare Diseases Informnation Center